Felicia F. Norwood
Felicia F. Norwood's purchase track record
How the stock did after each of Felicia F. Norwood's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/16/2023 | WFC | $1K | +8.6% | +11.3% | +13.8% |
| 10/18/2022 | WFC | $197 | -0.6% | -5.1% | +11.7% |
| 8/1/2022 | WFC | $1K | +6.3% | +7.7% | -2.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Wells Fargo, Merrill Lynch Pay $4.4M Fine for Commission Issues. Wells Fargo and Merrill Lynch agreed to pay $4.4 million to settle state regulator allegations regarding overcharged commissions on small-dollar trades. This regulatory action follows recent Q3 results that analysts suggest reset the company's narrative, with the stock currently trading near its 52-week low. The settlement is a modest financial event compared to the bank's overall scale and recent earnings performance.
Transaction History
| ELV | ▼ Sell | Tax Withholding | 496 | $141K | 3/3/2026 | View on chart |
| ELV | ▲ Buy | Grant | 5,951 | $0 | 3/2/2026 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 1,421 | $418K | 3/2/2026 | View on chart |
| ELV | ▲ Buy | Grant | 2,865 | $0 | 3/2/2026 | View on chart |
| ELV | ▲ Buy | Grant | 4,213 | $0 | 3/3/2025 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 2,613 | $1.0M | 3/3/2025 | View on chart |
| ELV | ▲ Buy | Grant | 3,035 | $0 | 3/3/2025 | View on chart |
| ELV | ▼ Sell | Open Market | 3,434 | $1.8M | 4/24/2024 | View on chart |
| ELV | ▼ Sell | Open Market | 2,765 | $1.5M | 4/24/2024 | View on chart |
| ELV | ▲ Buy | Option Exercise | 2,043 | $487K | 4/24/2024 | View on chart |
| ELV | ▼ Sell | Open Market | 100 | $53K | 4/23/2024 | View on chart |
| ELV | ▲ Buy | Option Exercise | 5,473 | $1.3M | 4/23/2024 | View on chart |
| ELV | ▼ Sell | Open Market | 14,011 | $7.5M | 4/23/2024 | View on chart |
| WFC | ▼ Sell | Other | 118 | $3K | 3/15/2024 | View on chart |
| ELV | ▲ Buy | Grant | 9,152 | $0 | 3/1/2024 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 4,902 | $2.4M | 3/1/2024 | View on chart |
| ELV | ▲ Buy | Grant | 2,405 | $0 | 3/1/2024 | View on chart |
| WFC | ▼ Sell | Other | 498 | $12K | 9/15/2023 | View on chart |
| WFC | ▲ Buy | Open Market | 77 | $1K | 3/16/2023 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 4,754 | $2.2M | 3/2/2023 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 495 | $232K | 3/1/2023 | View on chart |
| ELV | ▲ Buy | Grant | 2,292 | $0 | 3/1/2023 | View on chart |
| ELV | ▲ Buy | Grant | 9,716 | $0 | 3/1/2023 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 1,754 | $900K | 12/30/2022 | View on chart |
| WFC | ▲ Buy | Open Market | 5 | $89 | 10/18/2022 | View on chart |
| WFC | ▲ Buy | Open Market | 6 | $108 | 10/18/2022 | View on chart |
| WFC | ▲ Buy | Open Market | 9 | $170 | 8/1/2022 | View on chart |
| WFC | ▲ Buy | Open Market | 1 | $1K | 8/1/2022 | View on chart |
| WFC | ▲ Buy | Grant | 5,384 | $0 | 4/26/2022 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 446 | $207K | 3/2/2022 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 3,568 | $1.6M | 3/1/2022 | View on chart |
| ELV | ▲ Buy | Grant | 6,981 | $0 | 3/1/2022 | View on chart |
| ELV | ▲ Buy | Grant | 2,215 | $0 | 3/1/2022 | View on chart |
| ELV | ▼ Sell | Tax Withholding | 1,754 | $819K | 12/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Elevance Health Q3 Outlook: Premium Pressures and Sector Peer Trends
Elevance Health is preparing for its third-quarter earnings report, with analysts examining key metrics and the potential impact of lower premiums on the company's results. Broader sector news highlights peers like UnitedHealth, Centene, and Oscar Health pursuing growth and cost-saving strategies amidst shifting premium dynamics. The market is observing how these competitive and industry-wide pressures will align with Elevance Health's upcoming performance.
Elevance Health Q3 Outlook: Premium Pressures and Sector Peer Trends. Elevance Health is preparing for its third-quarter earnings report, with analysts examining key metrics and the potential impact of lower premiums on the company's results. Broader sector news highlights peers like UnitedHealth, Centene, and Oscar Health pursuing growth and cost-saving strategies amidst shifting premium dynamics. The market is observing how these competitive and industry-wide pressures will align with Elevance Health's upcoming performance.